Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Table 2

Treatment regimens in the pre- and post-2016 periods.

	Overall (n = 376)	1L pre-October 2016 cohort (n = 97)	1L post-October 2016 cohort (n = 279)
1L regimen distribution, n (%)
Gemcitabine + docetaxel	125 (33.2)	44 (45.4)	81 (29.0)
Olaratumab + doxorubicin	64 (17.0)	0 (0.0)	64 (22.9)
Gemcitabine	27 (7.2)	5 (5.2)	22 (7.9)
Doxorubicin + ifosfamide	25 (6.6)	7 (7.2)	18 (6.5)
Doxorubicin	24 (6.4)	13 (13.4)	11 (3.9)
Pazopanib	18 (4.8)	5 (5.2)	13 (4.7)
Dacarbazine + doxorubicin	16 (4.3)	3 (3.1)	13 (4.7)
Liposomal doxorubicin	12 (3.2)	7 (7.2)	5 (1.8)
Paclitaxel	10 (2.7)	3 (3.1)	7 (2.5)
Cyclophosphamide + dactinomycin + vincristine	5 (1.3)	2 (2.1)	3 (1.1)
Other 1L regimen	50 (13.3)	8 (8.2)	42 (14.1)
2L regimen distribution, n (%)
No 2L treatment observed	180 (47.9)	20 (20.6)	160 (57.3)
Gemcitabine + docetaxel	49 (13.0)	11 (11.3)	38 (13.6)
Pazopanib	24 (6.4)	13 (13.4)	11 (3.9)
Olaratumab + doxorubicin	23 (6.1)	5 (5.2)	18 (6.5)
Trabectedin	15 (4.0)	7 (7.2)	8 (2.9)
Doxorubicin	11 (2.9)	8 (8.2)	3 (1.1)
Gemcitabine	10 (2.7)	1 (1.0)	9 (3.2)
Eribulin mesylate	7 (1.9)	2 (2.1)	5 (1.8)
Olaratumab	6 (1.6)	2 (2.1)	4 (1.4)
Pembrolizumab	6 (1.6)	3 (3.1)	3 (1.1)
Doxorubicin + ifosfamide	5 (1.3)	4 (4.1)	1 (0.4)
Other 2L regimen	40 (10.6)	21 (21.6)	19 (6.8)
3L regimen distribution, n (%)
No 3L treatment observed	291 (77.4)	56 (57.7)	235 (84.2)
Olaratumab + doxorubicin	17 (4.5)	7 (7.2)	10 (3.6)
Trabectedin	15 (4.0)	9 (9.3)	6 (2.2)
Pazopanib	7 (1.9)	3 (3.1)	4 (1.4)
Gemcitabine + docetaxel	6 (1.6)	2 (2.1)	4 (1.4)
Other 3L regimen	40 (10.6)	20 (20.6)	20 (7.2)
1L to 2L treatment sequence distribution, n (%)
Gemcitabine + docetaxel > none	60 (16.0)	9 (9.3)	51 (18.3)
Gemcitabine + docetaxel > olaratumab + doxorubicin	19 (5.1)	5 (5.2)	14 (5.0)
Gemcitabine + docetaxel > pazopanib	11 (2.9)	7 (7.2)	4 (1.4)
Gemcitabine + docetaxel > doxorubicin	8 (2.1)	6 (6.2)	2 (0.7)
Gemcitabine + docetaxel > trabectedin	8 (2.1)	4 (4.1)	4 (1.4)
Other 1L to 2L treatment sequence^†	270 (71.8)	66 (68.0)	204 (73.1)

1L, first-line; 2L, second-line 3L, third-line. Regimens received by fewer than 5 patients in the study population were grouped into this category. In the 1L setting, 33 unique regimens each were received by fewer than 5 patients. In the 2L setting, 28 unique regimens each were received by fewer than 5 patients. In the 3L setting, 27 unique regimens each were received by fewer than 5 patients. ^†Treatment sequences received by fewer than 5 patients in the study population were grouped into this category. In total, 112 unique 1L to 2L treatment sequences were each received by fewer than 5 patients.